June 13 (Reuters) – Mesoblast Ltd on Monday said it
had regained full rights to its experimental stem cell therapy
for advanced chronic heart failure, which is currently in late
stage testing, from…
The post Mesoblast regains full rights to stem cell heart failure treatment appeared first on NASDAQ.